08 nov: Efter optur: Nordea sænker forventningerne til afkastet på aktier
08 nov: Nordea: Ingen ECB-renteforhøjelser i Draghis tid
08-11-2017 15:00:26

Zealand Pharma: Interim report for the first nine months of 2017

Relateret indhold
08:24 - 
Aktier/tendens: Danske Bank og Mærsk stjæler billedet
06:52 - 
Zealand/Jefferies: Lægger en tier til kursmålet efter g..
18 sep - 
Tirsdagens aktier: Pandora mistede lidt af pusten i grø..
Relateret debat
09:23 - 
Oversat, begivenheden gav uændret succesrate hos ..
09:16 - 
Du må tjekke hvad dine tal er udtryk for, og hvor..
08:54 - 
Det indlæg må du gerne finde. Novo må vel nærmest være ..

Company announcement - No. 50/2017

Interim report for the first nine months of 2017

Copenhagen, November 8, 2017 - Zealand Pharma A/S ("ZEAL") announces financial results and continued strong progress for its product candidates and business for the first nine months of 2017. Financial guidance for 2017 has been revised with 4-6% lower operating expenses.

Financial results for the first nine months of 2017

  • Revenue of DKK 128.5 million/USD 20.4 million[1] (DKK 54.3 million/USD 8.1 million2 in the first nine months of 2016).
  • Net operating expenses3 of DKK 251.7 million/USD 39.9 million1 (DKK 220.9 million/USD 33.1 million2 in the first nine months of 2016).
  • Net result of DKK -162.3 million/USD -25.7 million1 (DKK -206.7 million/USD -31.0 million2 in the first nine months of 2016).
  • Cash position of DKK 780.6 million/USD 123.8 million1 per September 30, 2017 (December 31, 2016: DKK 642.1 million/USD 91.0 million4, including restricted cash).

Business highlights for Q3 2017

  • Listing on the Nasdaq Global Select Market in the U.S. raising gross DKK 567 million/USD 90 million[1].

  • Initiation of Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.

  • Orphan drug designation for dasiglucagon for the treatment of congenital hyperinsulinism was granted by FDA in the U.S.

  • Boehringer Ingelheim initiated Phase 1 trial in the amylin analog program, triggering a EUR 4 million milestone payment to Zealand.

  • Boehringer Ingelheim initiated Phase 1 trial in the GLP-1/glucagon dual agonist program.

  • Soliqua® 100/33 revenue increased 37% and payer coverage increased 4%-point over the previous quarter to cover 65% of commercial lives.

Business highlights for the period thereafter

  • Orphan drug designation for glepaglutide for the treatment of short bowel syndrome granted by FDA in the U.S.

  • The potential for less than once-daily dosing with glepaglutide is being evaluated in a clinical trial, following positive results in the Phase 2 trial for Short Bowel Syndrome.

  • Patient enrolment completed for Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia.

  • Britt Meelby Jensen, President and CEO of Zealand

    , comments:

    "We continue to see strong results and progress with our clinical product candidates, and following the U.S. IPO in August, where we raised USD 90 million, we are in a solid position to advance our late stage clinical programs at full speed. For glepaglutide, we are in preparation to start Phase 3 mid-2018, we received orphan drug designation and we are finalizing a trial to assess the potential for a better dosing option for patients. In addition, two of our partnered programs have advanced to Phase 1 for treatment of obesity and/or diabetes. With this, I am convinced that Zealand is set for a successful future."

    Revised financial guidance for 2017 

    For 2017, Zealand maintains its revenue guidance of a continued increase in royalty payments from Sanofi. No specific guidance on the level of royalties can be provided as Sanofi has not provided any guidance on expected 2017 sales.

    Milestone revenue of DKK 101 million has been received from partners.

    Net operating expenses in 2017 are expected to be within the range of DKK 375-385 million, 4-6 % lower than previously guided (DKK 390-410 million). The decrease relates to timing of clinical studies as well as tight cost control.

    Operating loss before royalty income/expenses has been reduced from DKK 290-310 million to DKK 275-285 million.

    Conference call today at 4 pm CET/10 am EST

    Zealand's management will be hosting a conference call today at 4 pm CET/10 am EST to present the results for the first nine months of 2017. Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and Executive Vice President and Chief Medical and Development Officer Adam Steensberg. The presentation will be followed by a Q&A session.

    The dial-in numbers are:

    DK standard access             +45 32711658

    UK and international            +44 (0) 20 3427 1907

    U.S. (free dial-in)                 +1 646 254 3366

    Passcode                            3321181

    A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/m6/p/wr84wf2d also accessible on the Investor section of Zealand's website (www.zealandpharma.com). Participants are advised to register for the webcast approximately 10 minutes before the start. A recording of the event will be made available on the Investor section of Zealand's website after the call.

    For further information, please contact:

    Britt Meelby Jensen, President and Chief Executive Officer

    Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

    Mats Blom, Executive Vice President and Chief Financial Officer

    Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

    [1] Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.30 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2017.

    2 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 6.68 per USD 1.00, which was the rounded official exchange rate of such currencies at September 30, 2016.

    3 Net operating expenses consist of research, development and administrative expenses less other operating income.

    4 Translated solely for convenience into U.S. dollars at an assumed exchange rate of DKK 7.05 per USD 1.00, which was the rounded official exchange rate of such currencies at December 31, 2016.

    50-17_1108_ Interim Report for the first nine months


    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

    Source: Zealand Pharma via Globenewswire

    Vedhæftet fil: 824007.pdf

    Opret kommentar

    Relateret debat

    • 1 uge
    • 1 måned
    • 1 År
    00:18
    ZEAL
    Hold kæft en omgang gamle mavesure mænd at høre på.    Jeg har lige så meget lort da Vestas lå i 40,..
    16
    18 sep
    ZEAL
    Needham & Company analytiker Alan Carr løfter sit kursmål fra 26 $ (165 kr) til 29 $ (185 kr), som e..
    7
    14 sep
    ZEAL
    Nu er det ikke hvad Medwatch har skrevet vi taler om men hvad Britt Meelby Jensen har sagt vi diskut..
    6
    18 sep
    ZEAL
    Hvis der er dobbelt så god så er der vil ingen der gider at købe konkurenternes så må ZP da få et kæ..
    5
    17 sep
    ZEAL
    10 handelsdage tilbage af september, så nu må der snart være nyheder hver 2. dag, med mindre det hel..
    5
    12 sep
    ZEAL
    Han gemmer stadig sine 80 kr i banken, og håber en dag, at kunne købe en Zealand Aktie for dem.
    5
    07:38
    ZEAL
    Utroligt, at man 24/7 kan sidde og skabe sig over en ung biotekvirksomhed, der leverer det ene resul..
    4
    07:22
    ZEAL
    Alpe/Malurt kommentarer i Div aktier er på niveau med baronens - så glem dem
    4
    18 sep
    ZEAL
    Alpenyt - Du kan ikke andet end være negativ. ....Det er gamelt nyt. Det og det virker ikke. Der kom..
    4
    18 sep
    ZEAL
    BREAKING (for mig) Zealand har meddelt på web-cast at de vil lave en partneraftale på produktet... D..
    4

    Aktier/tendens: Danske Bank og Mærsk stjæler billedet

    19-09-2018 08:24:00
    Danske Bank og A.P. Møller-Mærsk vil på hver sin baggrund tage en stor del af opmærksomheden på det danske aktiemarked onsdag. Men også Ørsted vil blande sig i løjerne.Danske Bank-ledelsen fremlægger konklusionerne af en intern undersøgelse af den omfattende hvidvask af penge, der er foregået i Danske Banks estiske filial. Samtidig offentliggør A.P. Møller-Mærsk en længe ventet større organisation..

    Coloplast/dir: Skift i ambitionsniveauet er afgørende for væksten

    18-09-2018 15:10:18
    Den danske medicokoncern Coloplast har taget de første skridt i strategien om at få højere priser for klinisk dokumenterede produkter, og det kommer til at spille en afgørende rolle for selskabets vækst i fremtiden.- Det er ekstremt vigtigt. Vi opfatter det her skifte i ambitionsniveauet som afgørende for, at vi kan forøge vækstmomentum, siger Kristian Villumsen, der er direktør for den kroniske f..

    Mærsk/analytikere: Frasalg trak lidt ud men er nu så godt som i mål

    18-09-2018 13:45:01
    Når A.P. Møller-Mærsk næste år er klar til at sende Maersk Drilling, som ejer rigge og skibe, der borer efter olie og gas til havs på vegne af olieselskaberne, på børsen som et selvstændigt selskab, er koncernen også så godt som i mål med den ene del af strategien, som blev lanceret i 2016.På lørdag er det præcis to år siden, at Mærsk løftede sløret for en ny strategi, der skulle være med til at t..

    Mest læste nyheder

    • 24 timer
    • 48 timer
    • 1 uge
    1
    Pandora: Stiger på rygter i markedet om muligt bud - NY
    2
    Aktier/middag: Pandora banket op af italienske rygter
    3
    Novo Nordisk reorganiserer R&D - 400 medarbejdere afskediges - NY
    4
    Pandora/Sydbank: Lav værdisætning kan udnyttes af kapitalfonde
    5
    Aktier/tendens: Danske Bank og Mærsk stjæler billedet

    Relaterede aktiekurser

    Zealand Pharma A/S 118,80 0,7% Stigning i aktiekurs
    Zealand Pharma Aktiesels.. 118,60 0,5% Stigning i aktiekurs

    Køb- og salgsanbefalinger

    • Trend
    • Pengemaskinen

    Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
    Aktieinformation leveres af Morningstar.
    Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
     
    19. september 2018 09:24:28
    (UTC+01:00) Brussels, Copenhagen, Madrid, Paris
    Version: LiveBranchBuild_20180917.3 - EUROWEB3 - 2018-09-19 09:24:28 - 2018-09-19 09:24:28 - 1 - Website: OKAY